Pfizer India Seeks Emergency Use Authorization for Its Covid Vaccine
Pfizer India has become the first pharmaceutical company in India to approach Drugs Controller General of India (DCGI) seeking approval for emergency use of its Covid vaccine. The pharmaceutical firm submitted an application on December 4 to the DCGI seeking EUA or Emergency Use Authorization for its vaccine in India.
As per an official source, “Pfizer India has asked for permission for emergency use authorization of its coronavirus vaccine from Drugs Controller General of India to import and market”, said an official source. Pfizer India submitted the EUA application in Form CT-18 for grant of permission for Pfizer-BioNTech’s Covid-19 vaccine’s import and marketing.
In a recent all-party meeting, Prime Minister Narendra Modi said that a coronavirus vaccine can be expected to be ready in the next few weeks. As soon as approval by scientists is received, the vaccination will start.
Pfizer India made its move after Pfizer, its parent company got emergency-use clearance in the United Kingdom and Bahrain. On December 2, the UK became the first country in the world to approve emergency use of the Pfizer-BioNTech vaccine.
While the UK and Bahrain are ready for the immunization programme in their respective countries, India still awaits the use of a Covid-19 vaccine.
The only concern that experts have been raising is regarding logistical issues related to the distribution of the vaccine. The vaccine is required to be stored at a temperature of minus 70 degrees Celsius. However, most vaccines in India can be stored at temperatures between 2 and 8 degrees.
It is to be noted that on the morning of 7 December, the current number of cases in India has reached the tally of 96.77 Lakhs, with 32,981 new cases.
You May Like To Read:
What Happens When You are Infected with Coronavirus
Stay Fit & Active at Home During Coronavirus Lockdown
Healthy Foods to Boost Immune System Against Coronavirus
Disclaimer: This article is issued in general public interest and meant for general information purposes only. Readers are advised not to rely on the contents of the article as conclusive in nature and should research further or consult an expert in this regard.
